Large Scale Identification of Variant Proteins in Glioma Stem Cells
Ekaterina Mostovenko1, Ákos Végvári2, Melinda Rezeli2
1Department of Anatomy and Neurobiology, Virginia Commonwealth University School of Medicine , 1217 E. Marshall St., Richmond, Virginia 23284, United States.
Abstract:
Glioblastoma (GBM), the most malignant of primary brain tumors, is a devastating and deadly disease, with a median survival of 14 months from diagnosis, despite standard regimens of radical brain tumor surgery, maximal safe radiation, and concomitant chemotherapy. GBM tumors nearly always re-emerge after initial treatment and frequently display resistance to current treatments. One theory that may explain GBM re-emergence is the existence of glioma stemlike cells (GSCs). We sought to identify variant protein features expressed in low passage GSCs derived from patient tumors. To this end, we developed a proteomic database that reflected variant and nonvariant sequences in the human proteome, and applied a novel retrograde proteomic workflow, to identify and validate the expression of 126 protein variants in 33 glioma stem cell strains. These newly identified proteins may harbor a subset of novel protein targets for future development of GBM therapy.
Insights
Researchers identified 126 new protein variants in glioma stem-like cells (GSCs) from glioblastoma (GBM) tumors. These findings may lead to novel therapeutic targets for this deadly brain cancer.
Area of Science:
- Neuro-oncology
- Proteomics
- Cancer Stem Cell Biology
Background:
- Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis.
- GBM tumors often recur and resist current treatments, potentially due to glioma stem-like cells (GSCs).
Purpose of the Study:
- To identify novel protein variants expressed in low-passage GSCs derived from patient tumors.
- To discover potential new therapeutic targets for GBM.
Main Methods:
- Development of a proteomic database including variant and nonvariant human proteome sequences.
- Application of a novel retrograde proteomic workflow.
- Identification and validation of protein variants in 33 GSC strains.
Main Results:
- Successfully identified and validated 126 protein variants in GSCs.
- These variants represent potential targets for future GBM therapies.
Conclusions:
- The identified protein variants in GSCs offer a new avenue for developing targeted GBM therapies.
- This research contributes to understanding GBM recurrence and resistance mechanisms.
More Related Videos
12:25Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
Published on: January 7, 2014
06:32Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019